Adverse events referred to in other sections of this insert Eyelash changes (increased length, thickness, pigmentation , and number of lashes); eyelid skin darkening; intraocular inflammation (iritis/uveitis); iris pigmentation changes; and macular edema , including cystoid macular edema (see WARNINGS and PRECAUTIONS ). Controlled Clinical Trials The ocular adverse events and ocular signs and symptoms reported in 5 to 15% of the patients on XALATAN Sterile Ophthalmic Solution in the three 6-month, multi-center, double-masked , active-controlled trials were blurred vision , burning and stinging, conjunctival hyperemia, foreign body sensation , itching , increased pigmentation of the iris, and punctate epithelial keratopathy. Local conjunctival hyperemia was observed; however, less than 1% of the patients treated with XALATAN required discontinuation of therapy because of intolerance to conjunctival hyperemia. In addition to the above listed ocular events/signs and symptoms, the following were reported in 1 to 4% of the patients: dry eye , excessive tearing, eye pain , lid crusting, lid discomfort/pain, lid edema, lid erythema , and photophobia . The following events were reported in less than 1% of the patients: conjunctivitis , diplopia and discharge from the eye. During clinical studies, there were extremely rare reports of the following: retinal artery embolus , retinal detachment , and vitreous hemorrhage from diabetic retinopathy . The most common systemic adverse events
...
[ read more.. ]
Get A Second Opinion From...
|
